Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

Rivaroxaban (Xarelto) is an oral, direct factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. The aim was to compare the population pharmacokinetics (PK) and pharmacodynamics (PD) of twice-daily (bid) and once-daily (od) rivaroxaban in patients undergoing total hip replacement (THR). Blood samples were collected from patients enrolled in two phase IIb, dose-ranging studies undertaken to investigate rivaroxaban for thromboprophylaxis after THR. A sparse sampling technique was used and the samples were pooled for PK and PD analysis, which used non-linear mixed effect modelling. Rivaroxaban PK (samples from 758 patients) were well described by an oral, one-compartment model; age and renal function influenced clearance, and body surface area affected volume of distribution. When comparing the same total daily doses, maximum plasma concentrations of rivaroxaban were higher and minimum plasma concentrations were lower with od dosing, compared with bid dosing; however, the 90% intervals overlapped. The area under the plasma concentration-time curve was 18-30% higher in the od than in the bid study. Prothrombin time in seconds (samples from 1181 patients) correlated with rivaroxaban plasma concentrations in a linear fashion in both studies. In conclusion, the PK and PD of rivaroxaban were predictable when given either bid or od. These findings, along with the suggested efficacy and safety of rivaroxaban in the phase II studies, relative to enoxaparin, supported the selection of a convenient, once-daily 10 mg rivaroxaban dose for investigation in phase III studies.

[1]  W. Mueck,et al.  Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. , 2007, International journal of clinical pharmacology and therapeutics.

[2]  Carlo Bertucci,et al.  Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. , 2002, Current medicinal chemistry.

[3]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[4]  W. Mueck,et al.  The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor. , 2006 .

[5]  D. Murray,et al.  Risks and benefits of prophylaxis against venous thromboembolism in orthopaedic surgery. , 2000, The Journal of bone and joint surgery. British volume.

[6]  W. Mueck,et al.  Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects , 2007, Journal of clinical pharmacology.

[7]  C. Weinz,et al.  Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  D. Bergqvist,et al.  Current Options in the Prevention of Thromboembolic Disease , 2004, Drugs.

[9]  B. Eriksson,et al.  Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial. , 2007 .

[10]  M. Gent,et al.  BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study , 2005, Journal of thrombosis and haemostasis : JTH.

[11]  B. Eriksson,et al.  Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement , 2006, Journal of thrombosis and haemostasis : JTH.

[12]  B. Eriksson,et al.  Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. , 2007, Thrombosis research.

[13]  B. Eriksson,et al.  Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial. , 2007 .

[14]  G. Wensing,et al.  Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor , 2005, Clinical pharmacology and therapeutics.

[15]  D. Hoppensteadt,et al.  Anti-Xa and Anti-IIa Drugs Alter International Normalized Ratio Measurements: Potential Problems in the Monitoring of Oral Anticoagulants , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[16]  B. Clark.  Biology of renal aging in humans. , 2000, Advances in renal replacement therapy.

[17]  Clifford W Colwell,et al.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[18]  Michael Becka,et al.  Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects , 2005, European Journal of Clinical Pharmacology.

[19]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[20]  N. Bourgeois,et al.  Ageing and the liver. , 2006, Acta gastro-enterologica Belgica.

[21]  H. Büller,et al.  Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT). , 2007 .

[22]  D. Hoppensteadt,et al.  Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin , 2003, Clinical pharmacokinetics.

[23]  B. Eriksson,et al.  A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement , 2006, Circulation.

[24]  M. Gent,et al.  Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery , 2008, Clinical pharmacokinetics.